CBIZ, Inc. (NYSE: CBZ), a leading national professional services advisor, announced the release of its 2025 State of ...

Frier Levitt will host a May 15 webinar on legal risks, compounding regulations and market trends impacting GLP-1 prescribers ...

Novo Nordisk's competitive position is strengthening, driven by strong sales growth in Wegovy, Ozempic, and rare diseases.

Zealand Pharma A/S' obesity drug pipeline, including petrelintide, shows promise but faces high risks. Click to explore ZLDPF ...

Get a detailed overview of Wegovy’s dosage for ... To learn about your specific risk for serious side effects from Ozempic or Wegovy, talk with your doctor or pharmacist.

Developed by Simple Promise, ElectroSlim is a lemon-lime flavored, sugar-free fizzy drink powder designed to assist in weight ...

And for more information about Rybelsus, including details about its uses, see this Rybelsus overview article. Certain health conditions or other factors could raise your risk of harm if you take ...

Semaglutide is associated with a high prevalence of adverse events, and its long-term safety is unknown. In an observational ...

Despite its popularity, Ozempic often leads to temporary weight loss, carries serious side effects, and most users regain ...

While there's no advocacy for a complete ban in the study, the study urged people to proceed with caution, understanding the risks. Before prescribing Ozempic, a thorough check of an individual ...

A former head of the US Food and Drug Administration cut his body fat in half using GLP-1 drugs. In his book, he compares the ...

Novo Nordisk knew or should have known the causal association between the use of Ozempic and the risk of developing NAION, but they ignored it, the suit alleges. Jonathan Orent of Motley Rice.